Formatech will donate aseptic fill and finish services for one lot of a RegeneRx Biopharmaceuticals' drug candidate to treat cardiovascular and central nervous system diseases. The donation is part of the Massachusetts contract manufacturer's Fillanthropy Program, in which the company makes a monthly fill/finish donation to a company whose product is beginning human clinical trials.
The RegeneRx Biopharmaceuticals candidate, RGN-352, is an injectable formulation of a novel therapeutic peptide known as Thymosin Beta 4, targeted at conditions best treated via systemic delivery. RegeneRx is planning early-phase trials of RGN-352 as a treatment for multiple sclerosis.
Via the Fillanthropy Program, launched last August, Formatech made a similar donation recently to Tracon for its TRC102 small-molecule inhibitor of DNA base excision repair. The program has also awarded fills to GeoVax Labs for an HIV/AIDS vaccine candidate, to KAI Pharmaceuticals for its secondary hyperparathyroidism treatment, and to ViroMed for a vaccine targeting breast cancer.
- see the announcement